Inloggen

Login
 
Wachtwoord vergeten?

Axsome Therapeutics

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
53 Posts, Pagina: « 1 2 3 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
GeldIsOokNietAlles
0
Ook van het US-forum
everal hedge funds and other institutional investors have recently bought and sold shares of the stock. Alethea Capital Management LLC lifted its position in shares of Axsome Therapeutics by 65.9% during the 4th quarter. Alethea Capital Management LLC now owns 908,429 shares of the company’s stock worth $2,562,000 after purchasing an additional 360,986 shares during the last quarter. Worth Venture Partners LLC acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth about $138,000. Finally, Sio Capital Management LLC lifted its position in shares of Axsome Therapeutics by 115.5% during the 3rd quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock worth $1,437,000 after purchasing an additional 223,168 shares during the last quarter.
Helaas zonder bronvermelding

Nieuws van 30 januari: Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

finance.yahoo.com/news/axsome-therape...

adri67
0
Venrock Healthcare Capital Partners Ii, L.p. discloses 5.00% ownership in AXSM / Axsome Therapeutics, Inc.

January 28, 2019 - Venrock Healthcare Capital Partners Ii, L.p. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,640,000 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM). This represents 5.0 percent ownership of the company.
GeldIsOokNietAlles
0
quote:

adri67 schreef op 2 feb 2019 om 10:01:


Venrock Healthcare Capital Partners Ii, L.p. discloses 5.00% ownership in AXSM / Axsome Therapeutics, Inc.

January 28, 2019 - Venrock Healthcare Capital Partners Ii, L.p. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,640,000 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM). This represents 5.0 percent ownership of the company.


Heb je daar nog een bron Adri?
GeldIsOokNietAlles
0
Op de website van axsome staat over de pipeline niets meer vermeld over AXS-2
(https://axsome.com/axs-pipeline/overview/)
Terwijl bij de clinical trials er nog 2 onderzoeken hiervan in phase 3 zijn.
(https://clinicaltrials.gov/ct2/show/NCT02746068?term=axsome&rank=4 en
clinicaltrials.gov/ct2/show/NCT025040...
Weet iemand daar iets meer van? Zijn die toch gestopt? Was dat vorig jaar 2 januari het nieuws dat die resultaten tegenvielen en de reden dat de koers ruim 30% naar beneden ging?

Heb onderstaande gevonden:
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
Bron: globenewswire.com/news-release/2018/0...
adri67
0
GeldIsOokNietAlles
0
quote:

adri67 schreef op 2 feb 2019 om 14:00:


[...]
www.google.com/url?sa=t&rct=j&...


Thanks Adri, zo moeilijk was het inderdaad niet. Heb de vraag eigenlijk verkeerd gesteld. Ben op zoek naar een overzicht van alle institutionele partijen die in Axsome zitten.
GeldIsOokNietAlles
0
Short Interest (Shares Short) 1,804,200
Short Interest Ratio (Days To Cover) 0.2
Short Percent of Float 8.70 %
Short % Increase / Decrease 67 %
Short Interest (Shares Short) - Prior 1,083,400
Shares Float 20,749,400
Trading Volume - Average 9,629,600
Trading Volume - Today vs. Average 19.20%
% Owned by Insiders 30.40%
% Owned by Institutions 11.91%

Bron: shortsqueeze.com/shortinterest/stock/...
GeldIsOokNietAlles
0
Hoi Madeliefje, niet meer zo actief op IEX-forum?
Heb gisteren plukje MEIP gekocht. De upside lijkt me idd veel groter dan de downside. Ik denk wel dat je gebruik moet maken van de euforie bij goed nieuws en dan uitstappen. Leuk al die deals die ze hebben maar "voor wat, hoort wat".
Zit je nog steeds in AXSOME?
adri67
0
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation
GlobeNewswire•April 15, 2019

Demonstrated statistically significant reduction in daily smoking compared to active comparator (p=0.0016)

Trial conducted in collaboration with Duke University

NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Duke University has completed its topline analysis of the Phase 2 trial of AXS-05 for smoking cessation treatment. The analysis showed that AXS-05 met the prespecified primary endpoint and significantly reduced daily smoking as compared to the active comparator bupropion. The trial was conducted at the Duke Center for Smoking Cessation under a research collaboration between Axsome and Duke University. The Phase 2 study was a randomized, double-blind, active-controlled trial, in which 58 adult smokers were treated either with AXS-05 (45 mg dextromethorphan/105 mg bupropion), or the active comparator bupropion (105 mg), twice daily, and assessed over a 3-week period.

Treatment with AXS-05 resulted in a 25% greater reduction in the average number of cigarettes smoked per day over the 3-week period, the prespecified primary endpoint, as compared to bupropion (average reductions of 8.49 and 6.79 cigarettes per day for AXS-05 and bupropion, respectively, p=0.0016). Consistent with this finding, a greater proportion of smokers receiving AXS-05 experienced a more than 50% reduction in expired carbon monoxide levels, a biochemical marker of smoking intensity, as compared to those treated with bupropion (52.0% for AXS-05 versus 30.4% for bupropion, p=0.15). In addition, subjects who took AXS-05 as prescribed on a given day smoked 1.0 fewer cigarette on the day of medication use (p=0.026) and 1.2 fewer cigarettes on the following day (p=0.008) as compared to those who missed one or both doses.

“The findings in this trial are notable because AXS-05 was compared to bupropion, an approved treatment for smoking cessation.” said James Davis, MD, Medical Director of the Duke Center for Smoking Cessation, and principal investigator of the trial. “The improvement of AXS-05 over bupropion observed in this trial is similar in magnitude to the improvement over placebo reported for the approved smoking cessation treatment varenicline in studies with a similar design. Reduction in ad-lib smoking was selected as the primary endpoint in this trial, because it has been shown to correlate with smoking abstinence. I look forward to the continued evaluation of AXS-05 as a smoking cessation treatment.”

Medication adherence was similar between the study arms for both the morning dose (97.1% for AXS-05 and 96.6% for bupropion) and the evening dose (76.3% for AXS-05 and 79.4% for bupropion). In the study, AXS-05 was safe and well tolerated with no serious adverse events. The most commonly reported side effects were headache, dry mouth, and insomnia/vivid dreams, with similar incidences in both treatment arms.

“The topline results of this Phase 2 trial in smoking cessation add to the growing body of clinical data demonstrating biologic activity for AXS-05 in different areas of unmet medical need including major depressive disorder,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We would like to thank the team at the Duke Center for Smoking Cessation for their collaboration with Axsome and for the execution of this important trial. We look forward to continuing to analyze these results with the team at Duke and to determining the next steps for this program.”

“Smoking is widely recognized as the leading cause of preventable death and affects approximately 40 million adults in the U.S. alone,” said Cedric O’Gorman, MD, Senior Vice President of Clinical Development and Medical Affairs of Axsome. “Unfortunately, the vast majority of smokers who attempt to quit fail to do so highlighting the need for new approaches. We look forward to learning more about the potential of the novel mechanisms of action of AXS-05 to address this condition.”

AXS-05 is a novel, oral, NMDA receptor antagonist, also known as a glutamate receptor modulator, a potentially new mechanism of action for smoking cessation treatment. AXS-05 consists of dextromethorphan and bupropion, and utilizes Axsome’s metabolic inhibition technology to increase the bioavailability of dextromethorphan. Both components of AXS-05 are nicotinic acetylcholine receptor antagonists, a mechanism that is relevant to nicotine dependence.

About the Phase 2 Trial

The trial was a Phase 2, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of AXS-05 for smoking cessation treatment. A total of 58 smokers were randomized in a 1:1 ratio to receive either AXS-05 (45 mg dextromethorphan/105 mg bupropion) (n=31), or bupropion (105 mg) (n=27), twice daily, and assessed over a 3-week period. Enrolled subjects were daily smokers using 10 or more cigarettes per day. The average number of cigarettes smoked per day at baseline was 20 for AXS-05 and 17 for the bupropion treatment groups. The primary outcome measure was the change in smoking intensity, measured using the number of cigarettes smoked per day, assessed via daily smoking diaries. The trial was conducted at the Duke Center for Smoking Cessation.

About Smoking

Nearly 40 million American adults smoke and around 70% report that they want to quit. Tobacco use results in approximately 500,000 premature deaths each year in the U.S., according to the Centers for Disease Control and Prevention. Smoking is the single largest cause of premature deaths worldwide accounting for an estimated almost 20% of all deaths in developed countries [1]. Direct health care and lost productivity costs as a result of smoking total nearly $300 billion a year in the U.S. alone. It is estimated that only 3 to 5% of cigarette smokers who attempt to quit without assistance are successful for 6 to 12 months, and that relapse rates remain above 80% even with current treatments [2].

About AXS-05

AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of central nervous system (CNS) disorders. AXS-05 consists of dextromethorphan and bupropion and utilizes Axsome’s metabolic inhibition technology. The dextromethorphan component of AXS-05 is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, also known as a glutamate receptor modulator, which is a novel mechanism of action, meaning it works differently than currently available therapies for depression. The dextromethorphan component of AXS-05 is also a sigma-1 receptor agonist, nicotinic acetylcholine receptor antagonist, and inhibitor of the serotonin and norepinephrine transporters. The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is covered by more than 30 issued U.S. and international patents which provide protection out to 2034. AXS-05 is not approved by the FDA.
adri67
0
Here's Why You'll Regret Ignoring This Biotech Stock Rocket
Cory Renauer, The Motley Fool

Motley Fool • May 19, 2019

Taking two old drugs and combining them to treat depression was a roll of the dice that hardly anyone paid attention to during Axsome Therapeutics' (NASDAQ: AXSM) first few years as a publicly traded drugmaker. Clearly, that was a mistake.

At the beginning of 2019, this clinical-stage biotech was worth just under $80 million because its lead candidate seemed a little ridiculous. Since then, the stock has risen sevenfold and it's just getting started. Here's why you'll regret turning up your nose at Axsome in a few years, and probably a lot sooner.

So what if it's simple?

Axsome's lead candidate, AXS-05, is simply a combination of bupropion and dextromethorphan, two well-known drugs that make a dangerous combination because they amplify each other's effects. Bupropion is a norepinephrine and dopamine reuptake inhibitor that's been used to treat depression under the name Wellbutrin for decades. More recently, bupropion's been used as a smoking-cessation aid branded as Zyban, and off-label for attention-deficit hyperactivity disorder.

Bupropion's isn't nearly as common as dextromethorphan, a drug that nearly everyone has taken before and will probably take again. If you've swallowed anything to suppress a cough, it probably contained dextromethorphan, but that's not its only use. It's also a commonly abused over-the-counter medication that happens to amplify the effects of bupropion.

In fact, when someone regularly taking bupropion for depression, smoking cessation, or ADHD happens to chug a bottle of cough syrup, that person can end up in the hospital, or worse.

Major depressive disorder (MDD) affects around 6.7% of American adults, and available antidepressants aren't enough to break through for around one-third of them. Taking advantage of the interaction between the two drugs and finding the right balance seems obvious in retrospect, but Axsome was the first to combine a relatively small amount of both into a single tablet.

Beyond all expectations

Everyone who thought about boosting the power of bupropion with a measured dose of cough syrup but never did anything about it must be kicking himself right now. Few were paying attention to Axsome this January, but those who were had their minds blown.

During the phase 2 Ascend study, AXS-05 helped 47% of patients with MDD achieve clinical remission, compared with just 16% of patients in the group given bupropion on its own. The increased benefit isn't limited to depression, either. The amplification appears to carry over to bupropion's use as a smoking-cessation aid. During a 58-patient study, those taking AXS-05 smoked significantly less than those given bupropion on its own.
Axsome's ball to drop

During midstage studies, AXS-05 appeared just as safe and tolerable as bupropion monotherapy. Using two well-known drugs may not win awards for innovation, but it could help Axsome race along the path from a clinical-stage drugmaker to one with a product to sell. That's because the FDA is practically pushing the sorely needed new treatment option through the late-stage development process.

The FDA appears willing to accept a new drug application for the treatment of MDD based on results from the completed 80-patient Ascend study, instead of waiting for an ongoing phase 3 trial to wrap up. Unless Axsome forgets to include something in its new drug application, the company could receive an expedited review of AXS-05 and launch the potential blockbuster in the first half of 2020.

We have no idea where Axsome will price AXS-05, but it probably won't need to rely on an exorbitant sum to drive several billion in annual sales within a few short years. In the U.S. alone, there are roughly 7 million people suffering from treatment-resistant MDD, and they're clamoring for a better treatment option.

More on the way?

Axsome did so well with dextromethorphan and bupropion that it's ready to try another combination for the treatment of migraine headaches, and it's roaring forward at top speed. Before the end of the year, we could have phase 3 trial results for AXS-07, another combination of well-known drugs.

Rizatriptan is a powerful headache pain reliever that contracts blood vessels in the head, but it doesn't work for everyone. Meloxicam is a prescription-strength non-steroidal anti-inflammatory usually used to relieve arthritis symptoms.

After meeting with the FDA, Axsome is confident it can earn approval for AXS-07 without any early clinical-stage data -- just a single phase 3 trial should be enough. The phase 3 Momentum study has already finished enrolling people that don't respond to existing migraine pain relievers including rizatriptan.

We should be able to see results from the 875-patient Momentum trial before the end of 2019, which means Axsome could launch a second product for millions of underserved patients less than a year after AXS-05 reaches pharmacy shelves.
More fuel in the tank

Axsome Therapeutics stock has already soared 737% since the beginning of 2019, but its market cap is still just $786 million at recent prices. Drugmaker stocks generally trade at mid-single-digit multiples of trailing sales. With the FDA bending over backward to the company launch two potential blockbusters as quickly as possible, this stock probably has a lot more room to run over the next few years.
GeldIsOokNietAlles
0
Weer inside buy
www.nasdaq.com/symbol/axsm/insider-tr...

shorters weer 9% uitgebreid afgelopen 2 weken
shortsqueeze.com/shortinterest/stock/...

Dat is meer dan 50% van de freefloat (als je de freefloat in handen van instituties niet meetelt)
53 Posts, Pagina: « 1 2 3 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Markt vandaag

Wall Street kabbelt naar lager slot

14 okt De aandelenbeurzen in New York zijn maandag licht lager gesloten na een handelsdag zonder groot richtinggev...

    Indices

    AEX 575,21 -0,38%
    EUR/USD 1,1028 -0,07%
    Germany30^ 12.478,30 -0,07%
    Gold spot 1.491,27 -0,15%
    LDN100-24h 7.222,55 +0,44%
    NY-Nasdaq Composite 8.048,65 -0,10%
    US30# 26.849,79 +0,26%

    Stijgers

    Fagron
    +6,56%
    Basic-Fit
    +2,39%
    Alfen ...
    +2,24%
    Vastned
    +1,97%
    Sif Ho...
    +1,71%

    Dalers

    Arcelo...
    -2,57%
    ASR Ne...
    -1,62%
    RELX
    -1,57%
    AALBER...
    -1,35%
    Wolter...
    -1,33%